Chimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7-dependent tumors
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Martín Caballero, Juanca
- dc.contributor.author Garzón, Anaca
- dc.contributor.author González-Cintado, Leticiaca
- dc.contributor.author Kowalczyk, Wioletaca
- dc.contributor.author Jiménez Torres, Ignacioca
- dc.contributor.author Calderita, Gloriaca
- dc.contributor.author Rodríguez, Margaritaca
- dc.contributor.author Gondar, Virgíniaca
- dc.contributor.author Bernal, Juan Joseca
- dc.contributor.author Ardavín, Carlosca
- dc.contributor.author Andreu Martínez, Davidca
- dc.contributor.author Zürcher, Thomasca
- dc.contributor.author Kobbe, Cayetano vonca
- dc.date.accessioned 2015-05-13T08:07:59Z
- dc.date.available 2015-05-13T08:07:59Z
- dc.date.issued 2012ca
- dc.description.abstract Cervical cancer is caused by persistent high-risk human papillomavirus (HR-HPV) infection and represents the second most frequent gynecological malignancy in the world. The HPV-16 type accounts for up to 55% of all cervical cancers. The HPV-16 oncoproteins E6 and E7 are necessary for induction and maintenance of malignant transformation and represent tumor-specific antigens for targeted cytotoxic T lymphocyte–mediated immunotherapy. Therapeutic cancer vaccines have become a challenging area of oncology research in recent decades. Among current cancer immunotherapy strategies, virus-like particle (VLP)–based vaccines have emerged as a potent and safe approach. We generated a vaccine (VLP-E7) incorporating a long C-terminal fragment of HPV-16 E7 protein into the infectious bursal disease virus VLP and tested its therapeutic potential in HLA-A2 humanized transgenic mice grafted with TC1/A2 tumor cells. We performed a series of tumor challenge experiments demonstrating a strong immune response against already-formed tumors (complete eradication). Remarkably, therapeutic efficacy was obtained with a single dose without adjuvant and against two injections of tumor cells, indicating a potent and long-lasting immune response.en
- dc.description.sponsorship This work was supported in part by grants PIE/473/2009 and PIE/506/2008 from Instituto Madrileño de Desarrollo, 25/2008 from Comunidad Autónoma de Madrid, CIT-010000-2008-18 from Ministerio de Educación, FIT-010000-2007-68 from Ministerio de Industria, Turismo y Comercio, and CIT-010000-2007-34 from Ministerio de Ciencia e Innovación (PROFIT). Additional support was provided by Consorci Parc de Recerca Biomédica de Barcelona.en
- dc.format.mimetype application/pdfca
- dc.identifier.citation Martin Caballero J, Garzón A, González-Cintado L, Kowalczyk W, Jimenez Torres I, Calderita G et al. Chimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7-dependent tumors. PLoS ONE. 2012;7(12):e52976. DOI: 10.1371/journal.pone.0052976ca
- dc.identifier.doi http://dx.doi.org/10.1371/journal.pone.0052976
- dc.identifier.issn 1932-6203ca
- dc.identifier.uri http://hdl.handle.net/10230/23562
- dc.language.iso engca
- dc.publisher Public Library of Science (PLoS)ca
- dc.relation.ispartof PLoS ONE. 2012;7(12):e52976
- dc.rights © 2012 Martin Caballero et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are crediteden
- dc.rights.accessRights info:eu-repo/semantics/openAccessca
- dc.subject.other Papil·lomavirus -- Malaltiesca
- dc.subject.other Úter -- Càncerca
- dc.title Chimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7-dependent tumorsen
- dc.type info:eu-repo/semantics/articleca
- dc.type.version info:eu-repo/semantics/publishedVersionca